Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer

20191,463 citationsJournal Articlebronze Open Access

Authors

Kim N. · Prostate Cancer Canada

Neeraj Agarwal · University of Utah

Anders Bjartell · Skåne University Hospital

Byung Ha Chung · Yonsei University

Andrea Juliana Gomes

Robert Given · Eastern Virginia Medical School

Álvaro Juárez Soto

Axel S. Merseburger

Abstract

In this trial involving patients with metastatic, castration-sensitive prostate cancer, overall survival and radiographic progression-free survival were significantly longer with the addition of apalutamide to ADT than with placebo plus ADT, and the side-effect profile did not differ substantially between the two groups. (Funded by Janssen Research and Development; TITAN ClinicalTrials.gov number, NCT02489318.).

Topics & Keywords

Prostate Cancer Treatment and Research Radiopharmaceutical Chemistry and Applications Cancer, Lipids, and Metabolism

Publication Details

Published in: New England Journal of Medicine

Volume 381, Issue 1, pp. 13-24

DOI: 10.1056/nejmoa1903307

Field-Weighted Citation Impact: 126.87

Command Palette

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer

Authors

Abstract

Topics & Keywords

Publication Details